Search Results for "Growth"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Growth. Results 281 to 290 of 298 total matches.

Acute Reactions to Drugs of Abuse

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2002  (Issue 1125)
such as ataxia, and complications of pregnancy including fetal growth retardation and perinatal death. Dermal ...
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.
Med Lett Drugs Ther. 2002 Mar 4;44(1125):21-4 |  Show IntroductionHide Introduction

In Brief: One Drop or Two

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
to the labeling of all ADHD drugs against use in such patients. 3 Mild growth suppression has been reported ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49 |  Show IntroductionHide Introduction

Two New Drugs for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
pigmentation.10 In the pivotal trials, there was one report of hyperpigmentation and one of eyelash growth ...
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod (Vyzulta – Bausch and Lomb), a modified prostaglandin analog, and netarsudil (VRhopressa – Aerie), the first Rho kinase inhibitor to be approved in the US.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):117-20 |  Show IntroductionHide Introduction

Drugs for Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019  (Issue 1586)
mediator of neovascularization in wet AMD is thought to be vascular endothelial growth factor (VEGF ...
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-94 |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
has been associated with small decreases in growth velocity.12 MONTELUKAST — The oral leukotriene receptor ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for HFrEF

   
The Medical Letter on Drugs and Therapeutics • May 26, 2025  (Issue 1729)
PREGNANCY and LACTATION PREGNANCY and LACTATION . Have been associated with fetal growth ...
View the Comparison Chart: Some Drugs for HFrEF
Med Lett Drugs Ther. 2025 May 26;67(1729):e1-15   doi:10.58347/tml.2025.1729b |  Show IntroductionHide Introduction

Drugs for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025  (Issue 1719)
is thought to be vascular endothelial growth factor (VEGF), which induces angiogenesis and increases ...
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5   doi:10.58347/tml.2025.1719a |  Show IntroductionHide Introduction

Management of Opioid Withdrawal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018  (Issue 1554)
with an increased risk of complications such as preeclampsia, miscarriage, reduced fetal growth, fetal death ...
Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment. Withdrawal management without subsequent maintenance treatment is associated with high rates of relapse, overdose death, and HIV and/or hepatitis C virus infection. Several guidelines on management of opioid withdrawal are available. Maintenance treatment of opioid use disorder was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Aug 27;60(1554):137-42 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
corticosteroids during pregnancy has been associated with fetal growth restriction ▶ Combination is more ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction

Drugs for Common Bacterial Infections in Adults

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017  (Issue 1532)
and tetracycline hydrochloride: tooth discoloration and dys pla sia; inhibition of bone growth in fetus; hepatic ...
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse...
Med Lett Drugs Ther. 2017 Oct 23;59(1532):171-7 |  Show IntroductionHide Introduction